0001213900-24-056177.txt : 20240626 0001213900-24-056177.hdr.sgml : 20240626 20240626161502 ACCESSION NUMBER: 0001213900-24-056177 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240626 FILED AS OF DATE: 20240626 DATE AS OF CHANGE: 20240626 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Can-Fite BioPharma Ltd. CENTRAL INDEX KEY: 0001536196 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36203 FILM NUMBER: 241073588 BUSINESS ADDRESS: STREET 1: 26 BEN GURION STREET CITY: RAMAT GAN STATE: L3 ZIP: 5257346 BUSINESS PHONE: 972 39241114 MAIL ADDRESS: STREET 1: 26 BEN GURION STREET CITY: RAMAT GAN STATE: L3 ZIP: 5257346 6-K 1 ea0208540-6k_canfite.htm REPORT OF FOREIGN PRIVATE ISSUER

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of June 2024

001-36203

(Commission File Number)

CAN-FITE BIOPHARMA LTD.

(Exact name of Registrant as specified in its charter)

26 Ben Gurion Street

Ramat Gan 5257346 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On June 26, 2024, Can-Fite BioPharma Ltd. (the “Company”) convened the Annual General Meeting of Shareholders (the “Annual General Meeting”), however, the Annual General Meeting was adjourned for one week to the same day, time and place due to lack of quorum. Accordingly, the Company’s Annual General Meeting will be reconvened on Wednesday, July 3, 2024 at 3:00p.m., Israel time at the Company’s offices located at 26 Ben Gurion Street, Ramat Gan, Israel.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: June 26, 2024	By:	/s/ Motti Farbstein
		Motti Farbstein
		Chief Executive Officer and Chief Financial Officer